Related Experiment Video
Updated: May 10, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Statin treatment before percutaneous cononary intervention
Mario Leoncini1, Anna Toso, Mauro Maioli
1Cardiology Division of Prato Hospital, Prato, Italy.
Insights
Statins, or 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, benefit patients with coronary artery disease. These drugs may also protect the heart and kidneys during angioplasty by reducing injury.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are recommended for secondary prevention in patients with coronary artery disease (CAD).
- Statin pre-treatment may improve outcomes for patients undergoing percutaneous coronary intervention (PCI).
- Current guidelines recommend high-dose statins before PCI to reduce periprocedural myocardial infarction risk.
Purpose of the Study:
- To explore the potential cardiac and renal protective effects of statins in patients undergoing coronary angioplasty.
- To investigate the pleiotropic, non-lipid-lowering effects of statins contributing to cardio- and nephroprotection.
Main Methods:
- Review of existing literature and clinical guidelines on statin use in CAD and PCI.
- Analysis of proposed mechanisms for statin-mediated cardio- and nephroprotection.
Main Results:
- Statins improve short- and long-term prognosis in high-risk CAD patients and acute coronary syndrome.
- Statin pre-treatment is linked to better outcomes in PCI patients.
- Potential benefits extend beyond cardiac protection to include renal protection against contrast-induced acute kidney injury.
Conclusions:
- Statins offer significant benefits for secondary prevention in CAD.
- Pleiotropic effects of statins, such as improved endothelial function and reduced inflammation, contribute to both cardiac and renal protection.
- Statin use before PCI may mitigate both myocardial and renal injury, warranting further investigation.
Abstract:
Treatment with 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improves short-and-long term prognosis in high-risk patients with stable coronary artery disease and in those with acute coronary syndrome and their use is strongly recommended for secondary prevention. Moreover, recent data suggest that statin pre-treatment is associated with a better short- and long-term outcome in patients undergoing percutaneous coronary intervention. Current guidelines for coronary revascularization recommend the use of high-dose of statins before percutaneous coronary intervention to reduce the risk of periprocedural myocardial infarction in statin naïve patients (class IIa A) and in those on chronic statin therapy (class IIa B). However, the beneficial clinical effects elicited by statins in patients undergoing coronary angioplasty may arise not only from a cardiac protection against periprocedural myocardial injury but also from a renal protection against acute kidney injury caused by iodinated contrast media. Actually, statins exert multiple non-lipid lowering (pleiotropic) effects, including improved endothelial function, reduced inflammatory and immuno-modulatory processes, oxidative stress and platelet adhesion, that may contribute to both cardio- and nephro-protection even in the short-term.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:26Atherosclerosis III: Management
01:26Angina IV: Management
01:27Peripheral Artery Disease III: Interprofessional Care